exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087868 RNA Name: hsa-miR-195-5p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 7017667 End Site(bp): 7017687 External Links: hsa-miR-195-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABHD2 chr15 89087459 89202355 + AMER1 chrX 64185117 64205708 - ANKRD17 chr4 73073376 73258798 - ARHGAP35 chr19 46860997 47005077 + ASB1 chr2 238426742 238452250 + BACE1 chr11 117285207 117316259 - BIRC5 chr17 78214186 78225636 + CA12 chr15 63321378 63381846 - CYB561A3 chr11 61348745 61362299 - DCAF7 chr17 63550477 63594279 + ERG28 chr14 75649791 75660876 - FGFR1 chr8 38400215 38468834 - FLOT2 chr17 28879335 28897733 - FSD1 chr19 4304598 4323843 + KDSR chr18 63327726 63367228 - MAPK1IP1L chr14 55051647 55070194 + MRPS2 chr9 135499984 135504673 + MYB chr6 135181308 135219173 + PARM1 chr4 74933095 75050115 + PDE4A chr19 10416773 10469630 + PLPP6 chr9 4662294 4665258 + SCAMP4 chr19 1905372 1926013 + STEAP3 chr2 119223831 119265652 + TOB2 chr22 41433494 41446801 - TSPYL2 chrX 53082367 53088540 + ZBTB34 chr9 126860665 126885878 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0000458 chr12 124071293 124074996 + hsa_circ_0001699 chr7 40027197 40041630 + hsa_circ_0001387 chr4 1902352 1936989 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0000652 chr15 90984737 90986710 + hsa_circ_0001472 chr5 36953719 36976504 + hsa_circ_0001263 chr3 5215701 5216099 + hsa_circ_0000799 chr17 65941524 65972074 + hsa_circ_0001164 chr20 45891031 45923523 - hsa_circ_0000032 chr1 25666964 25669564 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand MIR29B2CHG chr1 207801518 207879115 - LINC00662 chr19 27681072 27794005 - AC002470.2 chr22 20979462 20998121 + NUTM2A-AS1 chr10 87201647 87342612 - SNHG1 chr11 62851984 62855953 - AC114980.1 chr5 93860669 93863825 - LINC01184 chr5 127939152 128083172 - SNHG25 chr17 64145970 64146476 + NEAT1 chr11 65422774 65445540 + AC021092.1 chr19 44103007 44113183 - AL391244.1 chr1 1420245 1422691 + SNHG12 chr1 28578538 28583132 - LINC02035 chr3 122886941 122892416 + AP000317.2 chr21 34073592 34360033 + NUTM2B-AS1 chr10 79661394 79826594 - MZF1-AS1 chr19 58559129 58574797 + MCM3AP-AS1 chr21 46229196 46259390 + XIST chrX 73820649 73852723 - AL359924.1 chr1 237862175 237928321 + AC020978.7 chr16 68224713 68227734 + AC021078.1 chr5 149494314 149504670 - AC003092.1 chr7 94022833 94066661 + SNHG16 chr17 76557764 76565348 + FGD5-AS1 chr3 14920347 14948424 - HCG18 chr6 30286690 30327382 - MIR503HG chrX 134543119 134546642 - LINC00649 chr21 33915534 33977691 + AC079781.5 chr7 97851688 97972985 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + AL031282.2 chr1 1702736 1737688 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.